pbs_code
stringlengths 5
6
| drug
stringclasses 15
values | brand
stringclasses 29
values | formulation
stringclasses 35
values | indication
stringclasses 7
values | treatment_phase
stringclasses 53
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 4.03k
4.03k
| schedule_year
int64 2.02k
2.02k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
11730J | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9662M | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13765L | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13765L | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13765L | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13765L | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13765L | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13765L | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13702E | baricitinib | Olumiant | Tablet 4 mg | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
10896L | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11488P | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | First continuing treatment | 14689 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
11488P | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | First continuing treatment | 14689 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
11488P | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | 14723 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
11488P | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | 14723 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
5734T | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5734T | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5734T | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5734T | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
11442F | baricitinib | Olumiant | Tablet 2 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11442F | baricitinib | Olumiant | Tablet 2 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5756Y | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
11515C | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | 9472 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
11515C | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | 9472 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
11217J | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
11217J | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
10072D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10072D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10072D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10072D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10072D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10072D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9657G | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9657G | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9657G | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9657G | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9657G | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9657G | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12794J | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12794J | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
11207W | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11207W | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3426H | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3426H | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3426H | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3426H | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12376J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12376J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12376J | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12376J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12376J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12376J | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12376J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12376J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12376J | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12376J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12376J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12376J | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13691N | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13691N | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13691N | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13691N | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13691N | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13691N | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12086D | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment in a patient weighing less than 30 kg | 14084 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |